Respiratory syncytial virus

FDA reviews safety of approved RSV antibodies for infants

2 weeks ago talkbio0Tagged AstraZeneca, Beyfortus, Infant, Merck, nirsevimab, palivizumab, Respiratory syncytial virus, RSV antibodies, safety review, sanofi, United States Food and Drug Administration

FDA; RSV; nirsevimab; Beyfortus; palivizumab; RSV antibodies; infant safety review; Sanofi; AstraZeneca; Merck; respiratory syncytial virus

Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx PCR Platform to Support Submission to the U.S. FDA

1 month ago talkbio0Tagged Clinical Evaluations, Co-Diagnostics, Co-Dx PCR platform, COVID19 (disease), Flu A/B, multiplex test, point-of-care, regulatory submission, Respiratory syncytial virus, United States Food and Drug Administration

Co-Diagnostics; clinical evaluations; multiplex test; point-of-care; Co-Dx PCR Platform; FDA 510(k); Flu A/B; COVID-19; RSV; regulatory submission

Enanta Presses Ahead with RSV Drug Zelicapavir Despite Missing Primary Endpoint in Phase IIb Trial

3 months ago talkbio0Tagged Clinical Trials, Congestive heart failure, COPD, development aspects, Elderly (population group), Enanta, Hospitalization, Neoplasm Metastasis, Phase II B Trial, primary endpoint, rates, Respiratory syncytial virus, United States Food and Drug Administration, Zelicapavir

Enanta Pharmaceuticals; RSV; zelicapavir; Phase IIb trial; primary endpoint miss; secondary endpoints; clinical trials; FDA Fast Track; elderly; COPD; congestive heart failure; hospitalization rates; future development

Sanofi Tightens Grip on RSV with $1.15B Upfront Acquisition of Vicebio, Diversifying Beyond mRNA Vaccines

5 months ago talkbio0Tagged Acquisition, Homo sapiens, Metapneumovirus, Molecular Clamp Technology, non-mRNA vaccine, Respiratory syncytial virus, respiratory vaccines, RSV, sanofi, vaccine pipeline, Vaccines, Combined, Vicebio

Sanofi; Vicebio; acquisition; RSV; human metapneumovirus; combination vaccine; Molecular Clamp technology; non-mRNA vaccine; vaccine pipeline; respiratory vaccines

RFK Jr.’s Revamped ACIP Votes Against Thimerosal in Flu Vaccines, Signaling Shift in Vaccine Policy

6 months ago talkbio0Tagged ACIP, Advisory Committees, anti-vaccine movement, Centers for Disease Control and Prevention (U.S.), Immunization, Influenza virus vaccine, Policy, Practice Experience, Respiratory syncytial virus, RFK Jr., thimerosal, Vaccines

RFK Jr.; ACIP; thimerosal; flu vaccine; vaccine policy; anti-vaccine movement; CDC; RSV shot; Advisory Committee on Immunization Practices

ACIP Backs Merck’s Enflonsia for RSV Prevention in Infants

6 months ago talkbio0Tagged ACIP, Children Program, Enflonsia, Immunization, Infant, Merck, Monoclonal Antibodies, Respiratory syncytial virus, RSV, Vaccines

ACIP; Merck; Enflonsia; RSV; monoclonal antibody; infants; immunization; Vaccines for Children Program

Merck Wins FDA Approval for RSV Antibody Drug, Intensifying Market Competition

7 months ago talkbio0Tagged Approved, AstraZeneca, competition, Enflonsia, Infant, Market, Merck, Monoclonal Antibodies, Respiratory syncytial virus, sanofi, United States Food and Drug Administration

Merck; FDA approval; RSV; monoclonal antibody; infants; Enflonsia; competitive market; Sanofi; AstraZeneca

Merck’s Enflonsia FDA Approval Spurs Sanofi to Accelerate Beyfortus Supply Ahead of 2025-26 RSV Season

7 months ago talkbio0Tagged Approved, AstraZeneca, Beyfortus, Enflonsia, Health care facility, Immunization, Infant, Merck, Respiratory syncytial virus, sanofi, supply chain, United States Food and Drug Administration

RSV; Infant immunization; Merck; Sanofi; Beyfortus; Enflonsia; FDA approval; supply chain; healthcare; AstraZeneca

CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s

8 months ago talkbio0Tagged 50–59, Adult, Age, Arexvy, broaden, Centers for Disease Control and Prevention (U.S.), Chronic Condition, Recommendation, Respiratory syncytial virus, Severe (severity modifier), Vaccines

Adult, Respiratory syncytial virus, Centers for Disease Control and Prevention (U.S.), Vaccines, Recommendation, Age, Arexvy, Chronic Condition, Severe (severity modifier), 50–59, broaden

Sanofi’s Beyfortus Achieves Blockbuster Status, Poised for Further Growth in US Market

11 months ago talkbio0Tagged Antibodies, Beyfortus, blockbuster sales, Growth, Infant, Market, Protection, Respiratory syncytial virus, sanofi, U.S.

Beyfortus, RSV antibody, Sanofi, blockbuster sales, US market growth, infant protection, respiratory syncytial virus